ORCA
Online Research @ Cardiff
Browse by All Cardiff Authors
 | Up a level |
Number of items: 28.
| Hamilton, Emma, Pearce, Laurence, Morgan, Liam, Robinson, Sophie, Ware, Victoria Lesley, Brennan, Paul, Thomas, N. Shaun B., Yallop, Deborah, Devereux, Stephen, Fegan, Christopher D., Buggins, Andrea G. S. and Pepper, Christopher John 2012. Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. British Journal of Haematology 158 (5) , pp. 589-599. 10.1111/j.1365-2141.2012.09191.x |
|
| Britt-Compton, Bethan, Lin, Thet Thet, Ahmed, G., Weston, V., Robinson, Rhiannon Elizabeth, Fegan, Christopher Daniel, Oscier, D. G., Stankovic, T., Pepper, Christopher John and Baird, Duncan Martin 2012. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage [Letter]. Leukemia 26 (4) , pp. 826-830. 10.1038/leu.2011.281 |
|
|
| Nunes, Claudia Trindade, Wong, Ryan Francis, Mason, Malcolm David, Fegan, Christopher Daniel, Man, Stephen Tzekwung and Pepper, Christopher John 2012. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research 18 (3) , pp. 678-687. 10.1158/1078-0432.CCR-11-2630 |
|
|
| Pepper, Christopher John, Majid, Aneela, Lin, Thet Thet, Hewamana, Saman, Pratt, Guy, Walewska, Renata, Gesk, Stefan, Siebert, Reiner, Wagner, Simon, Kennedy, Ben, Miall, Fiona, Davis, Zadie A., Tracy, Ian, Gardiner, Anne C., Brennan, Paul, Hills, Robert Kerrin, Dyer, Martin J. S., Oscier, David and Fegan, Christopher Daniel 2012. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. British Journal of Haematology 156 (4) , pp. 499-507. 10.1111/j.1365-2141.2011.08974.x |
|
|
| Nunes, Claudia Trindade, Miners, Kelly Louise, Dolton, Garry Michael, Pepper, Christopher John, Fegan, Christopher Daniel, Mason, Malcolm David and Man, Stephen Tzekwung 2011. A novel tumor antigen derived from enhanced degradation of Bax protein in human cancers. Cancer Research 71 (16) , pp. 5435-5444. 10.1158/0008-5472.CAN-11-0393 |
|
|
| Majid, Aneela, Lin, Thet Thet, Best, Giles, Fishlock, Keith, Hewamana, Saman, Pratt, Guy, Yallop, Deborah, Buggins, Andrea G. S., Wagner, Simon, Kennedy, Ben J., Miall, Fiona, Hills, Robert Kerrin, Devereux, Stephen, Oscier, David G., Dyer, Martin J. S., Fegan, Christopher Daniel and Pepper, Christopher John 2011. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leukemia Research 35 (6) , pp. 750-756. 10.1016/j.leukres.2010.10.022 |
|
|
| Pepper, Christopher John, Mahdi, J. G., Buggins, A. G. S., Hewamana, Saman, Walsby, Elisabeth Jane, Mahdi, Eamon, Al-Haza'a, A., Mahdi, Ali J., Lin, Thet Thet, Pearce, Laurence, Morgan, Liam David, Bowen, Ivor D., Brennan, Paul and Fegan, Christopher Daniel 2011. Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. Cell Proliferation 44 (4) , pp. 380-390. 10.1111/j.1365-2184.2011.00760.x |
|
|
| Pepper, Christopher John and Fegan, Christopher Daniel 2011. CLL: a supplementary question? Blood 117 (5) , pp. 1439-1440. 10.1182/blood-2010-11-318451 |
|
|
| Buggins, Andrea G. S., Pepper, Christopher John, Patten, Piers E. M., Hewamana, Saman, Gohil, Satyen, Moorhead, Jane, Folarin, Najeem'deen, Yallop, Deborah, Thomas, N. Shaun B., Mufti, Ghulam J., Fegan, Christopher Daniel and Devereux, Stephen 2010. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-κB activation and De novo gene transcription. Cancer Research 70 (19) , pp. 7523-7534. 10.1158/0008-5472.CAN-10-1634 |
|
|
| Lin, Thet Thet, Letsolo, Boitelo Theresiah, Robinson, Rhiannon Elizabeth, Rowson, Janet Maud, Pratt, Guy, Hewamana, Saman, Fegan, Christopher Daniel, Pepper, Christopher John and Baird, Duncan Martin 2010. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 116 (11) , pp. 1899-1907. 10.1182/blood-2010-02-272104 |
|
|
| Hartley, John A., Hamaguchi, Anzu, Coffils, Marissa, Martin, Christopher R. H., Suggitt, Marie, Chen, Zhizhi, Gregson, Stephen J., Masterson, Luke A., Tiberghien, Arnaud C., Hartley, Janet M., Pepper, Christopher John, Lin, Thet Thet, Fegan, Christopher Daniel, Thurston, David E. and Howard, Philip W. 2010. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity. Cancer Research 70 (17) , pp. 6849-6859. 10.1158/0008-5472.CAN-10-0790 |
|
|
| Pearce, Laurence, Morgan, Liam David, Lin, Thet Thet, Hewamana, Saman, Matthews, Reginald James, Deaglio, Silvia, Rowntree, Clare, Fegan, Christopher Daniel, Pepper, Christopher John and Brennan, Paul 2010. Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica 95 (3) , pp. 514-517. 10.3324/haematol.2009.014381 |
|
|
| Allan, J. M., Sunter, N. J., Bailey, J. R., Pettitt, A. R., Harris, R. J., Pepper, Christopher John, Fegan, Christopher Daniel, Hall, A. G., Deignan, L, Bacon, C. M., Pointon, J. C., Houlston, R. S., Broderick, P, Mainou-Fowler, T, Jackson, G. H., Summerfield, G, Evans, P. A., Strefford, J. C., Parker, A, Oscier, D, Pratt, G and Allsup, D. J. 2010. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia [Letter]. Leukemia 24 (4) , pp. 877-881. 10.1038/leu.2009.298 |
|
|
| Walsby, Elisabeth Jane, Pratt, G., Hewamana, Saman, Crooks, P. A., Burnett, Alan Kenneth, Fegan, Christopher Daniel. and Pepper, Christopher John 2010. The NF- B inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Molecular Cancer Therapeutics 9 (6) , pp. 1574-1582. 10.1158/1535-7163.MCT-10-0104 |
|
|
| Watkins, Catherine Louise, Brennan, Paul, Fegan, Christopher Daniel, Takayama, Kentaro, Nakase, Ikuhiko, Futaki, Shiroh and Jones, Arwyn Tomos 2009. Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. Journal of Controlled Release 140 (3) , pp. 237-244. 10.1016/j.jconrel.2009.04.028 |
|
|
| Pepper, Christopher John, Hewamana, Saman, Brennan, Paul and Fegan, Christopher Daniel 2009. NF-κB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncology 5 (7) , pp. 1027-1037. 10.2217/fon.09.72 |
|
|
| Brennan, Paul, Shore, Angharad M., Clement, Mathew, Hewamana, Saman, Jones, Catrin M., Giles, Peter James, Fegan, Christopher Daniel, Pepper, Christopher John and Brewis, Ian Andrew 2009. Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells. Proteomics - Clinical Applications 3 (3) , pp. 359-369. 10.1002/prca.200800137 |
|
|
| Hewamana, Saman, Lin, Thet Thet, Rowntree, Clare, Karunanithi, Kamaraj, Pratt, Guy, Hills, Robert Kerrin, Fegan, Christopher Daniel, Brennan, Paul and Pepper, Christopher John 2009. Rel A is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. Journal of Clinical Oncology 27 (5) , pp. 763-769. 10.1200/JCO.2008.19.1114 |
|
|
| Pratt, Guy, Harding, Stephen, Holder, Roger, Fegan, Christopher Daniel, Pepper, Christopher John, Oscier, David, Gardiner, Anne, Bradwell, Arthur R. and Mead, Graham 2009. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. British Journal of Haematology 144 (2) , pp. 217-222. 10.1111/j.1365-2141.2008.07456.x |
|
|
| Delgado, Julio, Pratt, Guy, Phillips, Neil, Briones, Javier, Fegan, Christopher Daniel, Nomdedeu, Josep, Pepper, Christopher John, Aventin, Anna, Ayats, Ramon, Brunet, Salut, Martino, Rodrigo, Valcarcel, David, Milligan, Donald and Sierra, Jorge 2009. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. British Journal of Haematology 145 (6) , pp. 801-805. 10.1111/j.1365-2141.2009.07699.x |
|
|
| Hewamana, Saman, Lin, Thet Thet, Jenkins, Chris, Burnett, Alan Kenneth, Jordan, Craig T., Fegan, Christopher Daniel, Brennan, Paul, Rowntree, Clare and Pepper, Christopher John 2008. The novel nuclear factor- B inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clinical Cancer Research 14 (24) , pp. 8102-8111. 10.1158/1078-0432.CCR-08-1673 |
|
|
| Pepper, Christopher John, Lin, Thet Thet, Pratt, Guy, Hewamana, Saman, Brennan, Paul, Hiller, Louise, Hills, Robert Kerrin, Ward, Rachel, Starczynski, Jane, Austen, Belinda, Hooper, Laura, Stankovic, Tatjana and Fegan, Christopher Daniel 2008. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112 (9) , pp. 3807-3817. 10.1182/blood-2008-05-157131 |
|
|
| Hewamana, Saman, Alghazal, Suhair Alkailani, Lin, Thet Thet, Clement, Matthew, Jenkins, Christopher, Guzman, Monica L., Jordan, Craig T., Neelakantan, Sundar, Crooks, Peter A., Burnett, Alan Kenneth, Pratt, Guy, Fegan, Christopher Daniel, Rowntree, Clare, Brennan, Paul and Pepper, Christopher John 2008. The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111 (9) , pp. 4681-4689. 10.1182/blood-2007-11-125278 |
|
|
| Lin, Thet Thet, Hewamana, Saman, Ward, Rachel Mary, Taylor, Hannah, Payne, Tammy, Pratt, Guy, Baird, Duncan Martin, Fegan, Christopher D. and Pepper, Christopher John 2008. Highly purified CD38+ sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38+ sub-populations derived from the same chronic lymphocytic leukaemia patient. British Journal of Haematology 142 (4) , pp. 595-605. 10.1111/j.1365-2141.2008.07236.x |
|
|
| Di Bernardo, Maria Chiara, Crowther-Swanepoel, Dalemari, Broderick, Peter, Webb, Emily, Sellick, Gabrielle, Wild, Ruth, Sullivan, Kate, Vijayakrishnan, Jayaram, Wang, Yufei, Pittman, Alan M, Sunter, Nicola J, Hall, Andrew G, Dyer, Martin J S, Matutes, Estella, Dearden, Claire, Mainou-Fowler, Tryfonia, Jackson, Graham H, Summerfield, Geoffrey, Harris, Robert J, Pettitt, Andrew R, Hillmen, Peter, Allsup, David J, Bailey, James R, Pratt, Guy, Pepper, Christopher John, Fegan, Christopher Daniel, Allan, James M, Catovsky, Daniel and Houlston, Richard S 2008. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia [Letter]. Nature Genetics 40 (10) , pp. 1204-1210. 10.1038/ng.219 |
|
|
| Milroy, L. G., Zinzalla, G., Loiseau, F., Qian, Z., Prencipe, G., Pepper, Christopher John, Fegan, Christopher Daniel and Ley, S. V. 2008. Natural-product-like spiroketals and fused bicyclic acetals as potential therapeutic agents for B-cell chronic lymphocytic leukaemia. ChemMedChem 3 (12) , pp. 1922-1935. 10.1002/cmdc.200800265 |
|
|
| Pepper, Christopher John, Thomas, Alun, Hoy, Terence George, Milligan, Donald, Bentley, Paul and Fegan, Christopher Daniel 2003. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 101 (7) , pp. 2454-2460. 10.1182/blood-2002-07-1984 |
|
|
| Pepper, Christopher John, Thomas, Alun, Hoy, Terence George, Tighe, Jane, Culligan, Dominic, Fegan, Christopher Daniel and Bentley, Paul 2003. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell Cycle 2 (1) , pp. 53-8. |
|
|
Cardiff University Information Services